NLRC4 and adult-onset Still disease: To date, promising results showed a favorable response toward Tadekinig-α in AOSD/sJIA and NLRC4-related MAS, which are currently under phase II and III, respectively (ClinicalTrials.gov Identifier: NCT02398435, NCT03113760, NCT03512314) [104,129,130,131].